mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition

BRAF inhibitors (BRAFi) and the combination therapy of BRAF and MEK inhibitors (MEKi) were recently approved for therapy of metastatic melanomas harbouring the oncogenic BRAFV600 mutation. Although these therapies have shown pronounced therapeutic efficacy, the limited durability of the response ind...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Xue, Gongda, Kohler, Reto, Tang, Fengyuan, Hynx, Debby, Wang, Yuhua, Orso, Francesca, Prêtre, Vincent, Ritschard, Reto, Hirschmann, Petra, Cron, Peter, Roloff, Tim, Dummer, Reinhard, Mandalà, Mario, Bichet, Sandrine, Genoud, Christel, Meyer, Alexandra G., Muraro, Manuele G., Spagnoli, Giulio C., Taverna, Daniela, Rüegg, Curzio, Merghoub, Taha, Massi, Daniela, Tang, Huifang, Levesque, Mitchell P., Dirnhofer, Stephan, Zippelius, Alfred, Hemmings, Brian A., Wicki, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Priority Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642473/
https://ncbi.nlm.nih.gov/pubmed/29050198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18213
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados